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Abstract: Marine cyanobacteria have been considered a rich source of secondary 
metabolites with potential biotechnological applications, namely in the pharmacological 
field. Chemically diverse compounds were found to induce cytoxicity, anti-inflammatory 
and antibacterial activities. The potential of marine cyanobacteria as anticancer agents has 
however been the most explored and, besides cytotoxicity in tumor cell lines, several 
compounds have emerged as templates for the development of new anticancer drugs. The 
mechanisms implicated in the cytotoxicity of marine cyanobacteria compounds in tumor 
cell lines are still largely overlooked but several studies point to an implication in 
apoptosis. This association has been related to several apoptotic indicators such as cell 
cycle arrest, mitochondrial dysfunctions and oxidative damage, alterations in caspase 
cascade, alterations in specific proteins levels and alterations in the membrane sodium 
dynamics. In the present paper a compilation of the described marine cyanobacterial 
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compounds with potential anticancer properties is presented and a review on the 
implication of apoptosis as the mechanism of cell death is discussed.  
Keywords: cancer; apoptosis; marine cyanobacteria; natural compounds 
 
1. Introduction 
Cyanobacteria are a diverse group of prokaryotic organisms that can exist in a wide range of 
ecosystems. Capable to develop photosynthesis, cyanobacteria constitute one of the components of the 
primary first level organisms in water food chains. These organisms have also important roles in 
nutrient cycles such as nitrogen cycle, by converting atmospheric nitrogen into an organic form, in a 
process that releases some residual hydrogen [1]. 
The first studies concerning cyanobacteria were focused on their ecological and public heath 
impact, due to their capacity to produce toxins with deleterious effects on plants, invertebrates and 
vertebrates, including humans [2,3]. In humans, toxins such as microcystins, nodularins and 
cylindrospermopsin were found to induce liver and kidney damage, cytotoxicity, neurotoxicity, dermal 
toxicity, gastrointestinal disturbances among others [4]. More recently, several studies have 
demonstrated that cyanobacteria also produce compounds with biotechnological and pharmaceutical 
interest. Important biological properties such as anticancer, anti-inflammatory and antibiotic activities 
have been described [5]. 
Marine cyanobacteria in particular have been considered a prominent source of structurally diverse 
and biologically active natural products [6]. The diversity in secondary metabolites is a result of the 
cyanobacterial capacity to integrate both Non-Ribosomal Peptide Synthethases with Polyketide 
Synthases. Cyanobacteria have a wide range of enzymes responsible for methylations, oxidations, 
tailoring and other alterations [7], resulting in chemically diverse natural products such as linear 
peptides [8], cyclic peptides [9], linear lipopeptides [10], depsipeptides [11], cyclic depsipeptides [12], 
fatty acid amides [13], swinholides [14], glicomacrolides [15] or macrolactones [16]. 
A large diversity of biological interactions is described between marine cyanobacteria compounds 
and several groups of organisms, such as bacteria [17], fungi [18,19] parasites [20] and invertebrates [21]. 
The role of the compounds in marine environment has been rarely elucidated but a possible 
explanation is that they represent a defensive handling to the surrounding predators [22]. In what 
concerns to humans, anti-inflammatory [23] neurotoxic [12] and anticancerigenous [24] are common 
bioactive properties. The cytotoxic effects of marine cyanobacteria compounds on human tumor cell 
lines are the most studied, with some compounds producing effects at the nanomolar range [25]. As 
examples, apratoxin D, produced by species of Lyngbya is potently cytotoxic to human lung cancer 
cells [26] and likewise, symplocamide A, isolated from Symploca sp. showed also potent cytotoxicity 
to lung cancer cells and neuroblastoma cells [27].  
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Cell death is crucial in cancer therapy. Comparing cell death mechanisms in neoplastic cells, 
apoptosis reveals its importance when compared with necrosis since it occurs as a physiological 
process to any mild cell injury or simply when cell function is finished or disturbed, occurs via a 
predictable and coordinated pathway, and cellular deletion does not involve inflammation [28]. In 
contrast, necrosis is difficult to prevent and always develops an inflammatory response and death of 
the surrounding cells [29]. Autophagy, also described as a mechanism of cell death, is likewise 
indicated as a cancer therapeutic target. However, it has a dual effect since maintaining cell survival 
can promote the growth of established tumors [30]. Several anticancer drugs work as apoptotic 
modulators, in order to eliminate silent and cleanly the unwanted cells [31,32]. Marine cyanobacteria 
were found to produce a wide range of compounds that revealed apoptotic properties. Apoptosis can be 
induced by both intrinsic and extrinsic signals, by multiple agents, as the natural flavonoid  
quercetin [33], the representative reactive oxygen species H2O2 [34] or even the UV radiation [35]. 
Apoptotic cells develop typical morphological alterations that allow its identification. During an early 
stage of apoptosis, called cell shrinkage, cells have a smaller size, showing a dense cytoplasm with 
thinner organelles [36]. Martins and co-workers demonstrated that HL-60 cells exposed to aqueous 
extracts of Synechocystis sp. and Synechococcus sp. strains, presented cell shrinkage showing that cells 
were developing apoptosis, and membrane budding, that occurs when cell is fragmented into apoptotic 
bodies [37]. Apoptotic cells also develop nuclear alterations, visible as nuclear fragmentation and 
chromatin condensation [36]. Biselyngbyaside, a macrolide glycoside produced by Lyngbya sp., was 
found to induce apoptosis in mature osteoclasts, revealed by nuclear condensation [38]. Marine benthic 
Anabaena sp. extracts were found to induce apoptosis in acute myeloid leukemia cell line, with cells 
showing several described typical morphological markers, such as chromatin condensation, nuclear 
fragmentation, surface budding and release of apoptotic bodies [39].  
Besides morphological markers that allow the direct identification of an apoptotic cell, some other 
cellular and molecular alterations associated to apoptosis can be identified. Since several marine 
cyanobacteria compounds interact with important molecular targets involved in anticancer activity 
leading to a controlled death of tumor cells, this review aims to resume the marine cyanobacterial 
products that were found to inhibit the proliferation of cancer cell lines, namely by inducing apoptotic 
cell death. Effects of compounds on cell cycle arrest, mitochondrial dysfunctions and oxidative 
damage, alterations in caspase cascade, non-caspases proteases involvement, alterations in the Bcl-2 
protein family and alterations in membrane sodium channel dynamics are reviewed. In order to 
summarize the data available in the literature, in Table 1 we present the described cyanobacterial 
compounds that were found to induce cytotoxic effects on a wide range of cancer cell line, and in 
Table 2 we describe the most relevant effects related to anticancer activity induced by marine 
cyanobacteria compounds. 
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Table 1. Marine cyanobacteria compounds with potential anticancer properties. 
Compound Source Class of compound Cytoxicity assay Human cell line tested Reference 
Ankaraholide A Geitlerinema Glycosilated swinholide
MTT NCI-H460 lung tumor [14] 
SRB MDA-MB-435 breast carcinoma [14] 
Apratoxin A Lyngbya majuscula Cyclic depsipeptide 
SRB 
KB oral epidermoid cancer and LoVo colon 
cancer 
[40,41] 
MTT 
U2OS osteosarcoma, HT29 colon 
adenocarcinoma and HeLa cervical carcinoma 
[42] 
Apratoxins B–C Lyngbya sp. Cyclic depsipeptides MTT 
KB oral epidermoid cancer and LoVo colon 
cancer 
[40] 
Apratoxin D 
Lyngbya majuscula 
and Lyngbya sordida 
Cyclic depsipeptide MTT H-460 lung cancer [26] 
Apratoxin E Lyngbya bouilloni Cyclic depsipeptide MTT 
U2OS osteosarcoma, HT29 colon 
adenocarcinoma and HeLa epithelial carcinoma 
[42] 
Apratoxins F and G Lyngbya bouilloni Cyclic depsipeptides 
MTT H-460 lung cancer [43] 
Hemocytometer 
counting 
HCT-116 colorectal cancer cells [43] 
Aurilide B Lyngbya majuscula Cyclic depsipeptide MTT H-460 lung tumor [24] 
Aurilide C Lyngbya majuscula Cyclic depsipeptide MTT NCI-H460 lung tumor [24] 
Belamide A Symploca sp. Linear tetrapeptide Non-specified HCT-116 colon cancer [8] 
Bisebromoamide Lyngbya sp. Peptide SRB HeLa S3 epithelial carcinoma [44] 
Biselyngbyaside Lyngbya sp. Glicomacrolide SRB 
HeLa S3 epithelial carcinoma, SNB-78 central 
nervous system cancer and NCI H522 lung cancer
[15] 
Calothrixin A Calothrix 
Pentacyclic 
indolophenanthridine 
3H-thymidine 
incorporation 
HeLa epithelial carcinoma [45] 
MTT Leukemia CEM [46] 
Calothrixin B Calothrix 
Pentacyclic 
indolophenanthridine 
MTT 
 
HeLa epithelial carcinoma [47] 
Leukemia CEM [46] 
Caylobolide A Lyngbya majuscula Macrolactone Non-specified HCT-116 colon tumor [48] 
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Caylobolide B Phormidium spp. Macrolactone MTT 
HT29 colorectal adenocarcinoma and HeLa 
cervical carcinoma 
[16] 
Coibamide A Leptolyngbya sp. Cyclic depsipeptide MTT 
Lung cancer NCI-H460, breast cancer  
MDA-MB-231, melanoma LOX IMVI, 
leukemia HL-60 and astrocytoma SNB75 
[49] 
Cryptophycin 1 Nostoc spp. Cyclic depsipeptide
Cell morphology 
examination 
MDA-MB-435 mammary adenocarcinoma and 
SKOV3 ovarian carcinoma 
[50] 
AlamarBlue dye 
reduction 
Leukemia U937, CCRF-CEM and HL-60, colon 
carcinoma HT-29, GC3 and Caco-2, mammary 
carcinoma MCF-7 and MDA-MB-231 and 
cervical carcinoma HeLa 
[51] 
Dolastatin 10 Symploca sp. Linear Pentapeptide
MTT 
Lung A549 carcinoma [52] 
Human lung cancer cells: NCI-H69, -H82,  
-H446 and -H510 
[53] 
Human DU-145 prostate cancer cell line [54] 
[3H] Thymidine Several lymphoma cell lines [55] 
Trypan blue dye Reh lymphoblastic leukemia [56] 
Dolastatin 12 Leptolyngbya sp. Cyclic depsipeptide MTT A549 lung carcinoma [52] 
Dragonamide Lyngbya majuscula Lipopeptide Non-specified 
A-549 lung epithelial adenocarcinoma, HT-29 
colon adenocarcinoma and MEL-28 melanoma
[57] 
Ethyl Tumonoate A 
Oscillatoria 
margaritifera 
Peptide MTT H-460 lung cancer [58] 
Hoiamide A 
Assemblage of Lyngbya 
majuscule and 
Phormidium gracile 
Cyclic depsipeptide Non-specified H-460 lung cancer [59] 
Hoiamide B Cyanobacterial sample Cyclic depsipeptide Non-specified H-460 lung cancer [59] 
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Homodolastatin 16 Lyngbya majuscula Cyclic depsipeptide MTT 
WHCO1 and WHCO6 esophageal cancer and 
ME180 cervical cancer 
[60] 
Isomalyngamide A and A-1 Lyngbya majuscula Fatty acid amides MTT Breast cancer MCF-7 and MDA-MB-231 [13] 
Jamaicamides A–C Lyngbya majuscula Polyketide-Peptides MTT H-460 lung cancer [61] 
Kalkitoxin Lyngbya majuscula Lipopeptide Trypan blue dye HCT-116 colon [62] 
Lagunamide C Lyngbya majuscula Cyclic depsipeptide MTT 
Lung adenocarcinoma A549, cancer prostate PC3, 
ileocecal colorectal cancer HCT8 and ovary cancer 
SK-OV 
[63] 
Largazole Symploca sp. Cyclic depsipeptide MTT 
MDA-MB-23I breast cancer and U2OS 
osteosarcoma 
[64] 
A549 lung cancer and HCT-116 colorectal carcinoma [65] 
Lyngbyabellin A Lyngbya majuscula Cyclic depsipeptide Non-specified 
KB nasopharyngeal carcinoma and LoVo colon 
adenocarcinoma 
[66] 
Lyngbyaloside Lyngbya sp. Glicomacrolide Non-specified 
KB nasopharyngeal carcinoma and LoVo colon 
adenocarcinoma 
[67] 
Majusculamide C Lyngbya majuscula Cyclic depsipeptide Non-specified 
Ovarian carcinoma OVCAR-3, kidney cancer A498, 
lung cancer NCI-H460, colorectal cancer KM20L2 
and glioblastoma SF-295 
[68] 
Malevamide D Symploca hydnoides Peptide ester Non-specified 
Lung cancer A-549, colon cancer HT-29 and 
melanoma MEL-28. 
[69] 
Malyngamide 2 Lyngbya sordida Fatty acid amine MTT H-460 lung cancer [23] 
Malyngamide C, J and K Lyngbya majuscula Fatty acid amines MTT H-460 lung cancer [70] 
Malyngolide dimmer Lyngbya majuscula Cyclodepside MTT H-460 lung cancer [71] 
Nostocyclopeptide A1 and A2 Nostoc sp. Cyclic heptapeptides Non-specified KB oral epidermoid cancer and LoVo colon cancer [72] 
Obyanamide Lyngbya confervoides Cyclic depsipeptide Non-specified KB oral epidermoid cancer and LoVo colon cancer [73] 
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Palauamide Lyngbya sp. Cyclic depsipeptide Non-specified 
Cervical carcinoma HeLa, lung adenocarcinoma A549 
and gastrocarcinoma BGC 
[74] 
KB oral epidermoid cancer [75] 
Palmyramide A Lyngbya majuscula Cyclic depsipeptide MTT H-460 lung cancer [76] 
Pitipeptolides A–B Lyngbya majuscula Cyclic depsipeptides
Non-specified LoVo colon cancer [77] 
MTT HT29 colon adenocarcinoma and MCF-7 breast cancer [17] 
Pitipeptolide C Lyngbya majuscula Cyclic depsipeptide MTT HT29 colon adenocarcinoma and MCF-7 breast cancer [17] 
Pitiprolamide Lyngbya majuscula Cyclic depsipeptide MTT 
HCT116 colorectal carcinoma and MCF7 breast 
adenocarcinoma 
[78] 
Pseudodysidenin Lyngbya majuscula Lipopeptide Non-specified 
A-549 lung adenocarcinoma, HT-29 colon 
adenocarcinoma and MEL-28 melanoma 
[57] 
Somocystinamide A Lyngbya majuscula Lipopeptide XTT 
Jurkat and CEM leukemia, A549 lung carcinoma,  
Molt4 T leukemia, M21 melanoma and U266 myeloma 
[79] 
Symplocamide Symploca sp. Cyclic peptide Non-specified H-460 lung cancer [27] 
Symplostatin 1 Symploca hydnoides Linear Pentapeptide SRB 
MDA-MB-435 breast carcinoma and  
NCI/ADR ovarian carcinoma 
[25] 
Epidermoid carcinoma cell line [80] 
Tasiamide Symploca sp. Cyclic peptide Non-specified KB oral epidermoid cancer and LoVo colon cancer [81] 
Tasiamide B Symploca sp. Peptide Non-specified KB oral epidermoid cancer [82] 
Tasipeptins A-B Symploca sp. Cyclic depsipeptides Non-specified KB oral epidermoid cancer [83] 
Ulongapeptin Lyngbya sp. Cyclic depsipeptide Non-specified KB oral epidermoid cancer [84] 
Veraguamides A-G Symploca cf. hydnoides Cyclic depsipeptides MTT H-460 lung cancer [85] 
Wewakazole Lyngbya sordida Cyclic dodecapeptide MTT H-460 lung cancer [23] 
Wewakpeptins Lyngbya semiplena Depsipeptides MTT H-460 lung cancer [11] 
MTT: 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide; XTT: 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide; SBR: Sulforhodamine B. 
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Table 2. Relevant anticancer cell effects induced by marine cyanobacteria compounds. 
Compound Source Class of compound Model tested Cell effect Reference 
Alotamide Lyngbya bouillonii Cyclic depsipeptide Murine cerebrocortical neurons Calcium influx promotion [12] 
Ankaraholide A Geitlerinema Glycosilated swinholide Rat aorta A-10 cells Loss of filamentous (F)-actin [14] 
Antillatoxin Lyngbya majuscula Lipopeptide 
Primary rat cerebellar granule cells Voltage-gated sodium channel 
activation 
[86] 
CHL 1610 Chinese hamster lung cells [87] 
Antillatoxin B Lyngbya majuscula Lipopeptide neuro-2a mouse neuroblastoma cells Sodium channel activation [10] 
Apratoxin A Lyngbya majuscula Cyclic depsipeptide 
Human HeLa cervical carcinoma cells Cell cycle inhibition [88] 
Human U2OS osteosarcoma cells Secretory pathway inhibition [89] 
Aurilide B Lyngbya majuscula Cyclic depsipeptide Rat aorta A-10 cells Microfilament disruption [24] 
Belamide A Symploca sp. Linear tetrapeptide Rat aorta A-10 cells Microtubule disruption [8] 
Bisebromoamide Lyngbya sp. Peptide 
Human HeLa epithelial carcinoma cells Actin filaments stabilization [90] 
Normal rat kidney cells extracellular 
signal regulated protein kinase 
Protein kinase inhibition [44] 
Bouillomides A–B Lyngbya bouillonii Depsipeptides Elastase and chymotrypsin Serine proteases inhibition [91] 
Calothrixin A Calothrix 
Pentacyclic 
indolophenanthridine 
Human leukemia CEM cells Cell cycle inhibition [46] 
Calothrixin B Calothrix 
Pentacyclic 
indolophenanthridine 
Human HeLa epithelial carcinoma cells Cell cycle inhibition [45] 
Human HeLa epithelial carcinoma cells Oxidative stress induction [45] 
Coibamide A Leptolyngbya sp. Cyclic depsipeptide Human NCI-H460 lung cancer cell line Cell cycle inhibition [49] 
Cryptophycin 1 Nostoc spp. Cyclic depsipeptide 
Human MDA-MB-435 mammary 
adenocarcinoma and SKOV3 ovarian 
carcinoma cells 
Cell cycle inhibition 
[50] 
 
Human MDA-MB-435 mammary 
adenocarcinoma 
Caspase-3 protein activation 
[50] 
 
Curacin A Lyngbya majuscula Lipopeptide 
Tubulin Tubulin polymerization inhibition [92] 
Human A549 lung carcinoma cells Bad protein levels increase [52] 
Human A549 lung carcinoma cells Caspase-3 protein activation [52] 
Bovine β-tubulin Tubulin polymerization inhibition [93] 
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Dolastatin 10 Symploca sp. Linear Pentapeptide 
Human Reh lymphoblastic leukemia cells Bcl-2 protein reduction [56] 
Human lung cancer cells: NCI-H69 and -H510 Bcl-2 protein phosphorylation [53] 
Human A549 lung carcinoma cells Bad protein levels increase [52] 
Human A549 lung carcinoma cells Caspase-3 protein activation [52] 
Dolastatin 12 Leptolyngbya sp. Cyclic depsipeptide Rat aorta A-10 cells Microfilament disruptor [94] 
Grassystatin A–B Lyngbya confervoides Linear depsipeptides Cathepsins D and E Proteases inhibition [95] 
Hectochlorin Lyngbya majuscula Lipopeptide Human CA46 Burkitt lymphoma cells Cell cycle inhibition [18] 
Hermitamides A–B Lyngbya majuscula Lipopeptide Human HEK embryonic kidney cells 
Voltage-gated sodium 
channel inhibition 
[96] 
Hoiamide A 
Assemblage of Lyngbya 
majuscule and 
Phormidium gracile 
Cyclic depsipeptide 
Primary cultures of neocortical neurons from 
embryonic mice 
Sodium channel activation [59,97] 
Hoiamide B Cyanobacterial sample Cyclic depsipeptide 
Primary cultures of neocortical neurons from 
embryonic mice 
Sodium influx stimulation [59] 
Kalkitoxin Lyngbya majuscula Lipopeptide Primary rat cerebellar granule neuron cultures Calcium influx inhibition [98] 
Kempopeptin A Lyngbya sp. Cyclic depsipeptide 
Bovine pancreatic α-chymotrypsin, porcine 
pancreatic elastase 
Serine Protease Inhibition [99] 
Kempopeptin B Lyngbya sp. Cyclic depsipeptide Trypsin Serine Protease Inhibition [99] 
Largamides A–C Lyngbya confervoides Cyclic depsipeptides Porcine pancreatic elastase Serine protease inhibition [100] 
Largamides D–G Oscillatoria sp. Cyclic depsipeptides α-chymotrypsin Serine protease inhibition [101] 
Lyngbyabellin A Lyngbya majuscula Cyclic depsipeptide 
Human CA46 Burkitt lymphoma cells Cell cycle inhibition [18] 
Rat aorta A-10 cells Microfilament disruption [66] 
Lyngbyabellin B Lyngbya majuscula Cyclic depsipeptide Human CA46 Burkitt lymphoma cells Cell cycle inhibition [18] 
Lyngbyastatin 1 Lyngbya majuscula Cyclic depsipeptide Rat aorta A-10 cells Microfilament disruption [94] 
Lyngbyastatin 4 Lyngbya confervoides Cyclic depsipeptide 
Bovine pancreatic α-chymotrypsin and porcine 
pancreatic elastase 
Serine protease inhibition [102] 
Lyngbyastatin 5–7 Lyngbya spp. Cyclic depsipeptides Porcine pancreatic elastase Serine protease inhibition [103] 
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Lyngbyastatin 8–10 Lyngbya semiplena Cyclic depsipeptides Porcine pancreatic elastase Serine protease inhibition [104] 
Malevamide E Symploca laete-viridis Depsipeptide Human HEK embryonic kidney cells Calcium influx inhibition [105] 
Molassamide Dichothrix utahensis Depsipeptide 
Bovine pancreatic α-chymotrypsin and 
porcine pancreatic elastase 
Serine protease inhibition [106] 
Palmyramide A Lyngbya majuscula Cyclic depsipeptide Mouse neuroblastoma neuro-2a cells Sodium channel inhibition [76] 
Palmyrolide 
Assemblage of 
Leptolyngbya cf. and 
Oscillatoria spp. 
Macrolide 
Mouse neuroblastoma neuro-2a cells Sodium influx inhibition [107] 
Murine cerebrocortical neurons 
Inhibition of calcium 
oscillations 
[107] 
Pitipeptolides A and B Lyngbya majuscula Cyclic depsipeptides Elastase Serine protease stimulation [77] 
Pompanopeptin A Lyngbya confervoides Cyclic peptide Porcine pancreatic trypsin Serine protease inhibition [108] 
Symplocamide Symploca sp. Cyclic peptide Chymotrypsin Serine protease inhibition [27] 
Symplostatin 1 Symploca hydnoides Linear Pentapeptide 
Rat aorta A-10 and human HeLa 
cervical carcinoma cells 
Cell cycle inhibition [25] 
Rat aorta A-10 cells 
Microtubule 
depolymerization 
[109] 
Human MDA-MB-435 breast carcinoma 
cells 
Bcl-2 phosphorylation [25] 
Human MDA-MB-435 breast carcinoma 
cells 
Caspase-3 protein activity 
stimulation 
[25] 
Symplostatin 3 Symploca sp.  Rat aorta A-10 cells 
Microtubule 
depolymerization 
[110] 
Tiglicamides A–C Lyngbya confervoides Cyclic depsipeptides Porcine pancreatic elastase Serine protease inhibition [111] 
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2. Cell Cycle Arrest 
Cell cycle is a delicate mechanism that comprises cell growth and its division into two daughter 
cells. Some substances are able to disturb the normal functioning of this mechanism compromising cell 
viability, a consequence that can be directly related with apoptosis. A common cellular damage 
induced by marine cyanobacteria compounds is the disruption of microtubules and actin  
proteins [112]. As these proteins are directly involved in mitosis, alterations in the normal functioning 
of the cell cycle occur. The most frequent consequence is G2/M phase arrest. Cryptophycin 52, a 
macrocyclic depsipeptide analogue of the naturally occurring cryptophycins isolated from the marine 
cyanobacteria Nostoc spp. [113], and calothrixin A, a indolophenanthridine isolated from Calothrix, 
are two examples of bioactive metabolites that induced, in different human cancer cell lines, a cell 
cycle arrest in G2/M phase [45]. Dolastatins are cytotoxic peptides that were initially isolated from the 
sea hare Dolabella auricularia and later found to be produced by marine cyanobacterial strains [109]. 
To explore their anticancer potential, several synthetic analogues were produced. Dolastatin 10, found 
in Symploca, and its non-cyanobacterial analogue, dolastatin 15, were both found to induce an arrest in 
the same cell cycle phase, G2/M phase, inducing apoptosis [52,114]. Symplostatin 1, another analogue 
of dolastatin 10 and cryptophycin 1, a dolastatin 52 analogue, were also responsible for a G2/M arrest 
in human cancer cells and for disturbances in the formation of mitotic spindles [25,113,114]. 
Calothrixin A, beyond an arrest in G2/M phase in a leukemia cell line at 1 μM and 10 μM, is also 
responsible for a cumulative arrest in S phase [46]. Hectochlorin and lyngbyabellins are structurally 
related lipopeptide and cyclic depsipeptides isolated from the genus Lyngbya. Both hectochlorin and 
lyngbyabellin B are described to induce an arrest in G2/M phase in a human Burkitt lymphoma cell 
line, accompanied with a related increase in binucleated cells and an apparent thickening of the 
microfilaments [18]. Nagarajan and co-workers [115] suggested that the inhibition of cell cycle 
proliferation by lyngbyabellins is assigned to a thiazole ring and dichlorinated components (Figure 1), 
once these compounds were all found to inhibit cell cycle proliferation [18,116].  
Figure 1. Chemical structures of the marine cyanobacterial secondary metabolites 
hectochlorin and lyngbyabellins A and B. 
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Figure 1. Cont. 
 
Besides G2/M phase arrest effects in G1 phase are also described. Khan and co-workers [46] 
reported a G1 phase arrest after treatment with a low concentration (0.1 μM) of calothrixin B. The 
same effect was demonstrated by Ma et al. [88] in a cervical carcinoma cell line treated with the cyclic 
depsipeptide apratoxin A (50 nM). Coibamide, a potent cytotoxic cyclic depsipeptide, founded in a 
Panamanian Leptolyngbya sp., was also described as capable to cause a significant dose dependent 
increase in the number of cells in G1 phase of the cell cycle [49]. 
3. Mitochondrial Dysfunctions and Oxidative Damage 
Mitochondria have essential functions in aerobic cells, and interferences in its normal behavior are 
crucial to determine cell fate [117]. A dysfunction in these organelles imbalances the cell redox 
potential, inducing damages in cell components that can lead, in the cases that pro-survival 
mechanisms fail, to apoptosis [118]. To the best of our knowledge, no study relating marine 
cyanobacterial natural products with mitochondrial dysfunctions has been done. However aurilide, a 
cyclodepsipeptide isolated from the sea hare Dolabella auricularia and related with the marine 
cyanobacterial aurilides A and B, is described to induce a dysfunction in mitochondria. HeLa cells, 
when treated with this metabolite exhibited mitochondria fragmentation, visible by MitoTracker Red 
staining [119].  
Oxidative stress is a cell condition that can be triggered by mitochondrial disorders. It can occur 
due to an overproduction of reactive oxygen species (ROS) or to a decrease in antioxidant levels [120]. 
Calothrixin A is described as an oxidative stress inducer in Jurkat human T cells, since they show an 
increase on intracellular ROS content after treatment with that molecule [45]. DNA damage is also a 
consequence directly associated to the oxidative stress, and it is commonly observed as a result of 
exposure to cyanobacterial secondary metabolites. As expected, besides an increase in ROS, 
calothrixin A foments DNA fragmentation [45]. DNA fragmentation is the most common DNA 
damage observed. Dolastatin 10 induced DNA damage on several human lymphoma cell lines [55] and 
on lung cancer cells [52]. Cryptophycins 1 and 52 are also metabolites that were found to induce DNA 
fragmentation [50,113].  
External nuclei alterations can be also a consequence of oxidative stress. Binucleated cells are 
frequently observed as a response to cyanobacterial products, as swinholide A, isolated from 
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cyanobacterial samples of Symploca cf. sp. [14] or lyngbyabellin [116]. Symplostatin 1 was found to 
induce an abnormal nuclear convolution in a rat aorta cell line, leading to the breakdown of nucleus 
and the formation of numerous micronuclei [25]. 
To counterbalance the deleterious effects of ROS, cells developed a complex antioxidant system. 
The antioxidant enzymes, like superoxide dismutase (SOD), catalase, glutathione-S-transferase (GST) 
and several peroxidases, constitute the front line, with important scavenging functions. Some other 
molecules, with low molecular weight, have crucial roles, such as glutathione, ascorbate or phenolic 
compounds [121]. The capacity of marine cyanobacterial natural products to interfere with the 
antioxidant system of human cells is not well elucidated. Evidences indicate that pigments are the 
compounds with higher antioxidant activity. Carotenoids isolated from the marine Trichodesmium are 
responsible for an antioxidative protection, observed with ferric reducing/antioxidant power  
assay [122]. In the same study, extracts from marine strains of Anabaena, Cyanothece, Prochlorothrix 
and Synechococcus showed antioxidant properties, but mainly in the protein extract [122]. Also the 
major phycobiliprotein, c-phycocyanin, from both Lyngbya and Phormidium, is capable to scavenge 
ROS, in particular peroxyl and hydroxyl radicals [123]. It was also suggested that this antioxidant 
capacity is resultant from the covalent linked tetrapyrole chromophore with phycocyanobilin [123].  
4. Alterations in Caspase Cascade 
Caspases are a family of cysteine aspartate proteases that act as the central executers of apoptosis. 
They are synthesized as inactive zymogens, which are activated after proteolytic cleavage [124]. 
According to their point of entrance into apoptotic process, caspases can be classified as initiators or 
effectors. Initiator caspases, that include -8, -9, and -10, activate the downstream effectors caspases,  
-3, -6 and -7, in a cascade of events that triggers a controlled and programmed cell death [125]. 
Marine cyanobacteria produce several compounds that are capable to induce alterations on caspases 
as a pathway to induce cell death. Several marine benthic cyanobacterial extracts showed to induce 
apoptosis partially dependent of protein caspases. Cells overexpressing LEDGF/p75, an inhibitor of 
cell death dependent of caspases, showed an increase in just a few number of apoptotic cells after 
treatment, when compared with the control [39]. 
Caspase-3 is the most studied caspase concerning to apoptosis induced by natural products. The 
activity of caspase-3 protein is increased after exposure to symplostatin 1 [25] and to the glicomacrolide 
biselyngbyaside [38]. Also cryptophycin 1 is described to induce apoptosis in a human ovarian 
carcinoma cell line, initiating the caspases cascade through caspase-3 activation [50]. The cleavage, 
and therefore the activation, of caspase-3 were still previously observed as a response to dolastatins 10 
and 15 and to the lipopeptide curacin A [52]. 
Cryptophycin 52 induced an apoptosis dependent on both caspase-3 and caspase-1 activation [113]. 
Another study [79] also reported that apoptosis induced by somocystinamide A, a lipopeptide from 
Lyngbya majuscula, occurs in a caspase-8 dependent manner, since it was observed an inhibition of 
tumor growth selectively in the caspase-8-expressing neuroblastoma cells, when compared with cells 
lacking the protein. 
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5. Non-Caspases Proteases Involvement 
Although caspases have a central role in the apoptotic cell death developing, it is described that the 
process often continues after an inhibition of this proteins [126,127]. This finding suggests the 
implication of other executors, which promote apoptosis in the absence of caspases. It was already 
proposed that some other proteases, capable to support apoptosis, have caspases amplification and 
assistance functions [128].  
Proteases are involved in the irreversibly hydrolysis of the peptide bonds in proteins, an important 
post-translational modification. These proteolytic enzymes are important for the control of a large 
number of key physiological processes, including apoptosis [129]. Apoptotic cell death induced by 
intracellular proteolysis of some serine proteases is already described [130]. Several cyanobacterial 
compounds have been described to interfere with the normal functioning of serine proteases, mainly 
the pancreatic elastase, chymotrypsin and trypsin, as is resumed in Table 3. Symplocamide A was 
described to inhibit chymotrypsin with an IC50 of 0.38 μM, with trypsin being also affected but with an 
IC50 of 80.2 μM, a difference greater than 200-fold [27]. The authors suggested that, to inhibit trypsin 
under 10 μM, a basic aminoacid residue between treonine (Thr) and 3-amino-6-hydroxy-2-piperidone 
(Ahp) is needed. A hydrophobic and neutral residue in this position confers to the compound a 
preference for chymotrypsin. Kempopeptins A and B are other two cyclodepsipeptides isolated from a 
Floridian collection of a marine Lyngbya sp. that reveal a strong potency to inhibit proteases  
activity [99]. Kempopeptin B, with a leucine (Leu) residue between Thr and Ahp (Figure 2), only 
inhibit trypsin activity (IC50 = 8.4 μM), but kempopeptin A, with a lysine (Lys) in the same position, 
inhibit both elastase (IC50 = 0.32 μM) and chymotrypsin (IC50 = 2.6 μM). Bouillomides A and B, two 
depsipeptides isolated from Lyngbya bouillonii and molassamide, a depsipeptide from Dichothrix 
utahensis, all dolastatin 13 analogues, contain 2-aminobutyric acid (Abu) between Thr and Ahp. As 
expected, these metabolites are chymotrypsin inhibitors [91,106]. Largamides are another family of 
cyclic peptides isolated from Lyngbya confervoides. Largamides D and E, with a Leu residue between 
Thr and Ahp, and largamides F and G, with a tyrosine (Tyr) in the same position, also inhibited 
chymotrypsin with IC50 range from 4.0 to 25.0 μM [101].  
Pompanopeptin A, a cyclic peptide isolated from the Lyngbya confervoides and kempopeptin B, 
contain arginine (Arg) and lysine (Lys), respectively, between Thr and Ahp. These basic residues give 
to the compounds the capacity to inhibit trypsin, pompanopeptin with an IC50 of 2.4 μM and 
kempopeptin with 8.4 μM [99,108]. 
Ahp residue-containing natural products are responsible for the inhibition of elastase [99]. 
Lyngbyastatins 4–10, a group of compounds that contain the Ahp residue, were all described as elastase 
inhibitors [102–104] with an IC50 range from 0.03 (lyngbyastatin 4) to 210 μM (lyngbyastatin 9). 
Lyngbyastatins are also strong chymotrypsin inhibitors, but with less potency than elastase,  
IC50 = 0.3 μM [99]. The same profile is verified with the depsipeptide molassamide witch contains the 
Ahp residue, which is capable to inhibit the elastase activity [106]. Largamides A–C and tiglicamides 
A–C, depsipeptides isolated from Lyngbya confervoides are non-containing Ahp natural compounds. 
However, these products were all responsible for an elastase enzyme inhibition [100,111]. 
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Table 3. Marine cyanobacteria natural products with an inhibitory effect in serine proteases. 
Compound Source Class of compound
Serine protease inhibition 
Reference 
Elastase Chymotripsin Thrypsin 
Bouillomide A Lyngbya bouillonii Depsipeptide IC50 = 1.9 μM IC50 = 0.17 μM No inhibition at 100 μM [91] 
Bouillomide B Lyngbya bouillonii Depsipeptide IC50 = 1.0 μM IC50 = 9.3 μM No inhibition at 100 μM [91] 
Kempopeptin A Lyngbya sp. Cyclic depsipeptide IC50 = 0.32 μM IC50 = 2.6 μM IC50 > 67 μM [99] 
Kempopeptin B Lyngbya sp. Cyclic depsipeptide IC50 > 67 μM IC50 > 67 μM IC50 = 8.4 μM [99] 
Largamide A Lyngbya confervoides Cyclic depsipeptide IC50 = 1.41 μM No inhibition at 50 μM No inhibition at 50 μM [100] 
Largamide B Lyngbya confervoides Cyclic depsipeptide IC50 = 0.53 μM No inhibition at 50 μM No inhibition at 50 μM [100] 
Largamide C Lyngbya confervoides Cyclic depsipeptide IC50 = 1.15 μM No inhibition at 50 μM No inhibition at 50 μM [100] 
Largamide D Oscillatoria sp. Cyclic depsipeptide Not described IC50 = 10.0 μM No inhibition [101] 
Largamide E Oscillatoria sp. Cyclic depsipeptide Not described IC50 = 10.0 μM No inhibition [101] 
Largamide F Oscillatoria sp. Cyclic depsipeptide Not described IC50 = 4.0 μM No inhibition [101] 
Largamide G Oscillatoria sp. Cyclic depsipeptide Not described IC50 = 25.0 μM No inhibition [101] 
Lyngbyastatin 4 Lyngbya confervoides Cyclic depsipeptide IC50 = 0.03 μM IC50 = 0.30 μM No inhibition at 30 μM [102] 
Lyngbyastatin 5 Lyngbya spp. Cyclic depsipeptide IC50 = 3.2 μM IC50 = 2.8 μM No inhibition at 30 μM [103] 
Lyngbyastatin 6 Lyngbya spp. Cyclic depsipeptide IC50 = 2.0 μM IC50 = 2.5 μM No inhibition at 30 μM [103] 
Lyngbyastatin 7 Lyngbya spp. Cyclic depsipeptide 
IC50 = 3.3 μM 
IC50 = 0.47 μM 
IC50 = 2.5 μM No inhibition at 30 μM [103,104] 
Lyngbyastatin 8 Lyngbya semiplena Cyclic depsipeptide IC50 = 0.12 μM Not described Not described [104] 
Lyngbyastatin 9 Lyngbya semiplena Cyclic depsipeptide IC50 = 0.21 μM Not described Not described [104] 
Lyngbyastatin 10 Lyngbya semiplena Cyclic depsipeptide IC50 = 0.12 μM Not described Not described [104] 
Molassamide Dichothrix utahensis Depsipeptide IC50 = 0.032 μM IC50 = 0.234 μM No inhibition at 10 μM [106] 
Pompanopeptin A Lyngbya confervoides Cyclic peptide Not described Not described IC50 = 2.4 μM [108] 
Symplocamide A Symploca sp. Cyclic peptide Not described IC50 = 0.38 μM IC50 = 80.2 μM [27] 
Somamide B 
Lyngbya majuscula and 
Schizothrix assemblage 
Depsipeptide IC50 = 9.5 μM IC50 = 4.2 μM No inhibition at 30 μM [103] 
Tiglicamide A Lyngbya confervoides Cyclic depsipeptide IC50 = 2.14 μM Not described Not described [111] 
Tiglicamide B Lyngbya confervoides Cyclic depsipeptide IC50 = 6.99 μM Not described Not described [111] 
Tiglicamide C Lyngbya confervoides Cyclic depsipeptide IC50 = 7.28 μM Not described Not described [111] 
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Figure 2. Chemical structures of the marine cyanobacterial secondary metabolites 
symplocamide and kempopeptins A and B. 
 
Pitipeptolides A and B, two cyclodepsipeptides isolated from the marine cyanobacteria  
Lyngbya majuscula collected at Guam, revealed a particular bioactivity. When in contact to elastase, 
these compounds induce a significant increase in activity: 2.76-fold and 2.55-fold, respectively, at  
50 μg/mL [77]. The authors suggested that this biological activity can be attributed to the presence of 
hydrophobic portions in the molecule [77]. 
Cathepsin D is a lysosomal protease that was described to have both anti-apoptotic [131] and  
pro-apoptotic functions [132]. Cathepsin E, besides its function being not well studied, it was 
described as a cathepsin D-like protein [133]. Grassystatins A and B, two linear depsipeptides isolated 
from Lyngbya confervoides were found to strongly inhibit cathepsins D (IC50 = 26.5 nM and 7.27 nM, 
respectively) and E (IC50 = 886 pM and 354 pM) [95]. 
6. Alterations in the Bcl-2 Protein Family 
The Bcl-2 protein family is one of the major apoptosis regulators, which functions in the 
modulation of the outer mitochondrial membrane. The antiapoptotic members Bcl-2 and Bcl-xL protect 
the membrane integrity and avoid the release of the cytochrome c, but their activity can be disturbed 
by the pro-apoptotic members Bax, Bad and Bid [28]. 
Symplostatin 1 initiates the phosphorylation of Bcl-2, inhibiting its anti-apoptotic properties in 
human breast cancer cells and the total content of the protein appear also to be decreased [25]. 
Exposure to cryptophycin 52 was responsible for Bcl-2 and Bcl-xL phosphorylation in several prostate 
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cancer cell lines [113]. Dolastatin 10 was associated to a Bcl-2 protein content reduction [56] and 
suggested to induce phosphorylation of the protein [53]. These are the common defensive mechanisms, 
the anti-apoptotic members are downregulated by phosphorylation, to allow the mechanisms of cell 
survival. However, cells can develop different ways of protection and, surprisingly, the synthetic 
analogue of dolastatin 10, dolastatin 15, promotes the overexpression of Bcl-2 protein in four different 
lung cancer cell lines [134]. 
Catassi and co-workers studied the response of non-small cell lung cancer cells when treated with 
curacin and dolastatins 10 and 15 and observed that these compounds inhibit Bad phosphorylation at 
serine136 [52]. The authors propose that the complex allow Bad to move into the mitochondria and 
promotes cytochrome c release, to trigger apoptosis [52]. Apart from the cell mechanism developed, 
the Bcl-2 protein family seems to play a crucial role in apoptosis induced by marine cyanobacterial 
natural compounds. 
7. Alterations in Membrane Sodium Channel Dynamics 
In mammal cells, a concentration gradient is necessary to keep the high levels of intracellular 
potassium and the low levels of sodium. This gradient is held by several ionic transporters and 
channels and by the capacity of cells to adapt to non-isotonic conditions, by volume regulatory 
mechanisms [135]. In apoptosis, a disordered volume regulation that leads to cell shrinkage during 
regular osmotic conditions occurs [136] leading to an early increase in the intracellular sodium 
concentration [137]. 
Marine cyanobacterial natural compounds seem to be involved in both induction and inhibition of 
sodium channels in neural cells. Antillatoxin, a lipopeptide isolated from Lyngbya majuscule was 
responsible for a rapid increase in sodium concentration inside of the cell in primary rat cerebellar 
granule cells [86]. Although the mechanism of interaction is not well described, the authors excluded 
an interaction of antillatoxin with channel neurotoxin sites 1–3, 5 and 7. Hoiamides are a class of 
cyclic depsipeptides with sodium channel bioactivity [59,97]. Hoiamides A and B were described to 
activate sodium channels in primary cultures of neocortical neurons from embryonic mice, with an 
IC50 of 1.7 μM and 3.9 μM, respectively [59]. In another work it was suggested that hoiamide A acts as 
a partial agonist at neurotoxin site 2 [97]. 
Palmyramide A, a cyclic depsipeptide from Lyngbya majuscule, showed to inhibit a veratridine and 
ouabain induced sodium overload with an IC50 value of 17.2 μM. The authors suggested that the 
inhibition may occur by blocking the voltage-gated sodium channel [76]. Palmyrolide, a macrolide 
isolated from an assemblage of Leptolyngbya cf. and Oscillatoria spp., is a stronger inhibitor of 
veratridine and ouabain induced sodium overload with an IC50 value of 3.70 μM [107]. 
Hermitamides A and B are two lipopeptides, isolated from the marine cyanobacteria Lyngbya 
majuscula from a Papua New Guinea collection. Hermitamide A is a sodium channel blocker that 
inhibits it near to 50% at 1 μM. Hermitamide B is a more potent blocker, inhibiting near to 80% at  
1 μM [96]. It was proposed that the aromatic region of these compounds is important for the channel 
inhibition, being the indole group of hermitamide B an advantage over the phenyl ring of hermitamide 
A. A bioinformatic approach reveals that the connection between hermitamide B and human  
voltage-gated sodium channel is driven mainly by a hydrophobic interaction with residue K1237, and 
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H-bonds between the amide group of hermitamide B with N434 and Y1586. Hydrophobic interactions 
between hermitamide B and F1283, F1579, L1582, V1583, Y1586, L1280, L788, F791, L792, I433, 
and L437 residues are also predicted [96].  
Alterations in intracellular sodium levels and the interaction between cyanobacterial natural 
products and the sodium channels are important keys to understand the toxic mechanism and to 
develop possible pharmacological applications.  
8. Conclusions  
Marine cyanobacteria have been identified as one of the most promising groups of organisms from 
which novel biochemically active natural products, with potential benefits against cancer, can be 
isolated. Although several compounds were found to inhibit cell growth in a large variety of cancer 
cell lines, the pathways by which cancer cells are inhibited are still poorly elucidated. In some cases, 
compounds were found to induce cell death by activation of the apoptotic process; nevertheless the 
mechanisms underlying the apoptosis still need more investigations. Some compounds were found to 
create an imbalance in cellular redox potential, with mitochondria representing a central role in the 
process. However, more studies are needed in order to clarify if mitochondria and oxidative stress are 
the direct targets, or if they are just a consequence of upstream damage. Cell cycle is another disturbed 
process, mainly due to disruption of the microtubules and actin filaments; however there are only a 
few studies connecting marine cyanobacterial compounds with alterations in cell cycle and more 
studies are needed in order to clarify the involvement of these compounds in the process. Not 
surprisingly, the proteins directly involved in apoptosis, caspases, non-caspases proteases and the  
Bcl-2 protein family, also seem to be associated with the cyanobacterial compounds activity. Even 
membrane sodium channels can establish interactions with the compounds, revealing its potentially 
important role in the observed effects. 
In summary, marine cyanobacteria seems to be clearly an important source of anticancer drugs. 
However, more investigations are needed in order to clarify the specific targets and the mechanisms 
that are behind cancer cell cytotoxicity, namely the involvement of the apoptotic process.  
Acknowledgements  
The authors acknowledge the Portuguese Foundation for Science and Technology (FCT) for 
financial support with the projects PTDC/MAR/102638/2008, PTDC/MAR/099642/2008, 
PTDC/MAR/102258/2008 and PesT-C/MAR/LA0015/2011. Margarida Costa has been supported with 
the FCT grant BTI/PTDC/MAR/102638/2008/2010-025. 
References 
1. Tsygankov, A.A. Nitrogen-Fixing cyanobacteria: Producents of hydrogen. Prikl. Biokhim. 
Mikrobiol. 2007, 43, 279–288. 
2. Carmichael, W.W. Cyanobacteria secondary metabolites—the cyanotoxins. J. Appl. Bacteriol. 
1992, 72, 445–459. 
Mar. Drugs 2012, 10 2199 
 
 
3. Codd, G.A.; Morrison, L.F.; Metcalf, J.S. Cyanobacterial toxins: Risk management for health 
protection. Toxicol. Appl. Pharmacol. 2005, 203, 264–272. 
4. Blaha, L.; Babica, P.; Marsalek, B. Toxins produced in cyanobacterial water blooms—toxicity 
and risks. Interdiscip. Toxicol. 2009, 2, 36–41. 
5. Singh, R.K.; Tiwari, S.P.; Rai, A.K.; Mohapatra, T.M. Cyanobacteria: An emerging source for 
drug discovery. J. Antibiot. (Tokyo) 2011, 64, 401–412. 
6. Nunnery, J.K.; Mevers, E.; Gerwick, W.H. Biologically active secondary metabolites from 
marine cyanobacteria. Curr. Opin. Biotechnol. 2010, 21, 787–793. 
7. Jones, A.C.; Monroe, E.A.; Eisman, E.B.; Gerwick, L.; Sherman, D.H.; Gerwick, W.H. The 
unique mechanistic transformations involved in the biosynthesis of modular natural products 
from marine cyanobacteria. Nat. Prod. Rep. 2010, 27, 1048–1065. 
8. Simmons, T.L.; McPhail, K.L.; Ortega-Barria, E.; Mooberry, S.L.; Gerwick, W.H. Belamide A, a 
new antimitotic tetrapeptide from a Panamanian marine cyanobacterium. Tetrahedron Lett. 2006, 
47, 3387–3390. 
9. Sisay, M.T.; Hautmann, S.; Mehner, C.; Konig, G.M.; Bajorath, J.; Gutschow, M. Inhibition of 
human leukocyte elastase by brunsvicamides A–C: Cyanobacterial cyclic peptides. 
ChemMedChem 2009, 4, 1425–1429. 
10. Nogle, L.M.; Okino, T.; Gerwick, W.H. Antillatoxin B, a neurotoxic lipopeptide from the marine 
cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2001, 64, 983–985. 
11. Han, B.; Goeger, D.; Maier, C.S.; Gerwick, W.H. The wewakpeptins, cyclic depsipeptides from a 
Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. J. Org. Chem. 
2005, 70, 3133–3139. 
12. Soria-Mercado, I.E.; Pereira, A.; Cao, Z.; Murray, T.F.; Gerwick, W.H. Alotamide A, a novel 
neuropharmacological agent from the marine cyanobacterium Lyngbya bouillonii. Org. Lett. 
2009, 11, 4704–4707. 
13. Chang, T.T.; More, S.V.; Lu, I.H.; Hsu, J.C.; Chen, T.J.; Jen, Y.C.; Lu, C.K.; Li, W.S. 
Isomalyngamide A, A-1 and their analogs suppress cancer cell migration in vitro. Eur. J. Med. 
Chem. 2011, 46, 3810–3819. 
14. Andrianasolo, E.H.; Gross, H.; Goeger, D.; Musafija-Girt, M.; McPhail, K.; Leal, R.M.; 
Mooberry, S.L.; Gerwick, W.H. Isolation of swinholide A and related glycosylated derivatives 
from two field collections of marine cyanobacteria. Org. Lett. 2005, 7, 1375–1378. 
15. Teruya, T.; Sasaki, H.; Kitamura, K.; Nakayama, T.; Suenaga, K. Biselyngbyaside, a macrolide 
glycoside from the marine cyanobacterium Lyngbya sp. Org. Lett. 2009, 11, 2421–2424. 
16. Salvador, L.A.; Paul, V.J.; Luesch, H. Caylobolide B, a macrolactone from symplostatin  
1-producing marine cyanobacteria Phormidium spp. from Florida. J. Nat. Prod. 2010, 73,  
1606–1609. 
17. Montaser, R.; Paul, V.J.; Luesch, H. Pitipeptolides C–F, antimycobacterial cyclodepsipeptides 
from the marine cyanobacterium Lyngbya majuscula from Guam. Phytochemistry 2011, 72, 
2068–2074. 
18. Marquez, B.L.; Watts, K.S.; Yokochi, A.; Roberts, M.A.; Verdier-Pinard, P.; Jimenez, J.I.;  
Hamel, E.; Scheuer, P.J.; Gerwick, W.H. Structure and absolute stereochemistry of hectochlorin, 
a potent stimulator of actin assembly. J. Nat. Prod. 2002, 65, 866–871. 
Mar. Drugs 2012, 10 2200 
 
 
19. Milligan, K.E.; Marquez, B.L.; Williamson, R.T.; Gerwick, W.H. Lyngbyabellin B, a toxic and 
antifungal secondary metabolite from the marine cyanobacterium Lyngbya majuscula. J. Nat. 
Prod. 2000, 63, 1440–1443. 
20. Tripathi, A.; Puddick, J.; Prinsep, M.R.; Rottmann, M.; Tan, L.T. Lagunamides A and B: 
Cytotoxic and antimalarial cyclodepsipeptides from the marine cyanobacterium Lyngbya 
majuscula. J. Nat. Prod. 2010, 73, 1810–1814. 
21. Capper, A.; Cruz-Rivera, E.; Paul, V.; Tibbetts, I. Chemical deterrence of a marine cyanobacterium 
against sympatric and non-sympatric consumers. Hydrobiologia 2006, 553, 319–326. 
22. Tan, L.T.; Goh, B.P. Chemical ecology of marine cyanobacterial secondary metabolites: A  
mini-review. J. Coast. Dev. 2009, 13, 1–9. 
23. Malloy, K.L.; Villa, F.A.; Engene, N.; Matainaho, T.; Gerwick, L.; Gerwick, W.H.  
Malyngamide 2, an oxidized lipopeptide with nitric oxide inhibiting activity from a Papua New 
Guinea marine cyanobacterium. J. Nat. Prod. 2011, 74, 95–98. 
24. Han, B.; Gross, H.; Goeger, D.E.; Mooberry, S.L.; Gerwick, W.H. Aurilides B and C, cancer cell 
toxins from a Papua New Guinea collection of the marine cyanobacterium Lyngbya majuscula.  
J. Nat. Prod. 2006, 69, 572–575. 
25. Mooberry, S.L.; Leal, R.M.; Tinley, T.L.; Luesch, H.; Moore, R.E.; Corbett, T.H. The molecular 
pharmacology of symplostatin 1: A new antimitotic dolastatin 10 analog. Int. J. Cancer 2003, 
104, 512–521. 
26. Gutierrez, M.; Suyama, T.L.; Engene, N.; Wingerd, J.S.; Matainaho, T.; Gerwick, W.H. 
Apratoxin D, a potent cytotoxic cyclodepsipeptide from papua new guinea collections of the 
marine cyanobacteria Lyngbya majuscula and Lyngbya sordida. J. Nat. Prod. 2008, 71,  
1099–1103. 
27. Linington, R.G.; Edwards, D.J.; Shuman, C.F.; McPhail, K.L.; Matainaho, T.; Gerwick, W.H. 
Symplocamide A, a potent cytotoxin and chymotrypsin inhibitor from the marine cyanobacterium 
Symploca sp. J. Nat. Prod. 2008, 71, 22–27. 
28. Ulukaya, E.; Acilan, C.; Yilmaz, Y. Apoptosis: Why and how does it occur in biology? Cell 
Biochem. Funct. 2011, 29, 468–480. 
29. Han, S.I.; Kim, Y.S.; Kim, T.H. Role of apoptotic and necrotic cell death under physiologic 
conditions. BMB Rep. 2008, 41, 1–10. 
30. Kim, M.K.; Suh, D.H.; Seoung, J.; Kim, H.S.; Chung, H.H.; Song, Y.S. Autophagy as a target for 
anticancer therapy and its modulation by phytochemicals. J. Food Drug Anal. 2012, 20, 241–245. 
31. Zhang, J.Y. Apoptosis-Based anticancer drugs. Nat. Rev. Drug Discov. 2002, 1, 101–102. 
32. Fischer, U.; Schulze-Osthoff, K. Apoptosis-Based therapies and drug targets. Cell Death Differ. 
2005, 12, 942–961. 
33. Chen, D.; Daniel, K.G.; Chen, M.S.; Kuhn, D.J.; Landis-Piwowar, K.R.; Dou, Q.P. Dietary 
flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. 
Pharmacol. 2005, 69, 1421–1432. 
34. Mao, Y.B.; Song, G.; Cai, Q.F.; Liu, M.; Luo, H.H.; Shi, M.X.; Ouyang, G.; Bao, S.D. Hydrogen 
peroxide-induced apoptosis in human gastric carcinoma MGC803 cells. Cell Biol. Int. 2006, 30, 
332–337. 
Mar. Drugs 2012, 10 2201 
 
 
35. Lytvyn, D.I.; Yemets, A.I.; Blume, Y.B. UV-B overexposure induces programmed cell death in a 
BY-2 tobacco cell line. Environ. Exp. Bot. 2010, 68, 51–57. 
36. Elmore, S. Apoptosis: A review of programmed cell death. Toxicol. Pathol. 2007, 35, 495–516. 
37. Martins, R.F.; Ramos, M.F.; Herfindal, L.; Sousa, J.A.; Skaerven, K.; Vasconcelos, V.M. 
Antimicrobial and cytotoxic assessment of marine cyanobacteria—Synechocystis and 
Synechococcus. Mar. Drugs 2008, 6, 1–11. 
38. Yonezawa, T.; Mase, N.; Sasaki, H.; Teruya, T.; Hasegawa, S.; Cha, B.Y.; Yagasaki, K.;  
Suenaga, K.; Nagai, K.; Woo, J.T. Biselyngbyaside, isolated from marine cyanobacteria, inhibits 
osteoclastogenesis and induces apoptosis in mature osteoclasts. J. Cell Biochem. 2012, 113,  
440–448. 
39. Oftedal, L.; Selheim, F.; Wahlsten, M.; Sivonen, K.; Doskeland, S.O.; Herfindal, L. Marine 
benthic cyanobacteria contain apoptosis-inducing activity synergizing with daunorubicin to kill 
leukemia cells, but not cardiomyocytes. Mar. Drugs 2010, 8, 2659–2672. 
40. Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. New apratoxins of marine cyanobacterial 
origin from Guam and Palau. Bioorg. Med. Chem. 2002, 10, 1973–1978. 
41. Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J.; Corbett, T.H. Total structure determination 
of apratoxin A, a potent novel cytotoxin from the marine cyanobacterium Lyngbya majuscula.  
J. Am. Chem. Soc. 2001, 123, 5418–5423. 
42. Matthew, S.; Schupp, P.J.; Luesch, H. Apratoxin E, a cytotoxic peptolide from a guamanian 
collection of the marine cyanobacterium Lyngbya bouillonii. J. Nat. Prod. 2008, 71, 1113–1116. 
43. Tidgewell, K.; Engene, N.; Byrum, T.; Media, J.; Doi, T.; Valeriote, F.A.; Gerwick, W.H. 
Evolved diversification of a modular natural product pathway: Apratoxins F and G, two 
cytotoxic cyclic depsipeptides from a Palmyra collection of Lyngbya bouillonii. ChemBioChem 
2010, 11, 1458–1466. 
44. Teruya, T.; Sasaki, H.; Fukazawa, H.; Suenaga, K. Bisebromoamide, a potent cytotoxic peptide 
from the marine cyanobacterium Lyngbya sp.: isolation, stereostructure, and biological activity. 
Org. Lett. 2009, 11, 5062–5065. 
45. Chen, X.X.; Smith, G.D.; Waring, P. Human cancer cell (Jurkat) killing by the cyanobacterial 
metabolite calothrixin A. J. Appl. Phycol. 2003, 15, 269–277. 
46. Khan, Q.A.; Lu, J.; Hecht, S.M. Calothrixins, a new class of human DNA topoisomerase I 
poisons. J. Nat. Prod. 2009, 72, 438–442. 
47. Bernardo, P.H.; Chai, C.L.; Le Guen, M.; Smith, G.D.; Waring, P. Structure-Activity delineation 
of quinones related to the biologically active Calothrixin B. Bioorg. Med. Chem. Lett. 2007, 17, 
82–85. 
48. MacMillan, J.B.; Molinski, T.F. Caylobolide A, a unique 36-membered macrolactone from a 
Bahamian Lyngbya majuscula. Org. Lett. 2002, 4, 1535–1538. 
49. Medina, R.A.; Goeger, D.E.; Hills, P.; Mooberry, S.L.; Huang, N.; Romero, L.I.; Ortega-Barria, E.; 
Gerwick, W.H.; McPhail, K.L. Coibamide A, a potent antiproliferative cyclic depsipeptide  
from the Panamanian marine cyanobacterium Leptolyngbya sp. J. Am. Chem. Soc. 2008, 130, 
6324–6325. 
50. Mooberry, S.L.; Busquets, L.; Tien, G. Induction of apoptosis by cryptophycin 1, a new 
antimicrotubule agent. Int. J. Cancer 1997, 73, 440–448. 
Mar. Drugs 2012, 10 2202 
 
 
51. Wagner, M.M.; Paul, D.C.; Shih, C.; Jordan, M.A.; Wilson, L.; Williams, D.C. In vitro 
pharmacology of cryptophycin 52 (LY355703) in human tumor cell lines. Cancer Chemother. 
Pharmacol. 1999, 43, 115–125. 
52. Catassi, A.; Cesario, A.; Arzani, D.; Menichini, P.; Alama, A.; Bruzzo, C.; Imperatori, A.;  
Rotolo, N.; Granone, P.; Russo, P. Characterization of apoptosis induced by marine natural 
products in non small cell lung cancer A549 cells. Cell. Mol. Life Sci. 2006, 63, 2377–2386. 
53. Kalemkerian, G.P.; Ou, X.L.; Adil, M.R.; Rosati, R.; Khoulani, M.M.; Madan, S.K.; Pettit, G.R. 
Activity of dolastatin 10 against small-cell lung cancer in vitro and in vivo: Induction of 
apoptosis and bcl-2 modification. Cancer Chemother. Pharm. 1999, 43, 507–515. 
54. Turner, T.; Jackson, W.H.; Pettit, G.R.; Wells, A.; Kraft, A.S. Treatment of human prostate 
cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate 1998, 
34, 175–181. 
55. Beckwith, M.; Urba, W.J.; Longo, D.L. Growth inhibition of human lymphoma cell lines by the 
marine products, dolastatins 10 and 15. J. Natl. Cancer Inst. 1993, 85, 483–488. 
56. Wall, N.R.; Mohammad, R.M.; Al-Katib, A.M. Bax:Bcl-2 ratio modulation by bryostatin 1 and 
novel antitubulin agents is important for susceptibility to drug induced apoptosis in the human 
early pre-B acute lymphoblastic leukemia cell line, Reh. Leuk. Res. 1999, 23, 881–888. 
57. Jimenez, J.I.; Scheuer, P.J. New lipopeptides from the Caribbean cyanobacterium Lyngbya 
majuscula. J. Nat. Prod. 2001, 64, 200–203. 
58. Engene, N.; Choi, H.; Esquenazi, E.; Byrum, T.; Villa, F.A.; Cao, Z.; Murray, T.F.;  
Dorrestein, P.C.; Gerwick, L.; Gerwick, W.H. Phylogeny-Guided isolation of ethyl tumonoate A 
from the marine cyanobacterium cf. Oscillatoria margaritifera. J. Nat. Prod. 2011, 74,  
1737–1743. 
59. Choi, H.; Pereira, A.R.; Cao, Z.; Shuman, C.F.; Engene, N.; Byrum, T.; Matainaho, T.;  
Murray, T.F.; Mangoni, A.; Gerwick, W.H. The hoiamides, structurally intriguing neurotoxic 
lipopeptides from Papua New Guinea marine cyanobacteria. J. Nat. Prod. 2010, 73, 1411–1421. 
60. Davies-Coleman, M.T.; Dzeha, T.M.; Gray, C.A.; Hess, S.; Pannell, L.K.; Hendricks, D.T.; 
Arendse, C.E. Isolation of homodolastatin 16, a new cyclic depsipeptide from a Kenyan 
collection of Lyngbya majuscula. J. Nat. Prod. 2003, 66, 712–715. 
61. Edwards, D.J.; Marquez, B.L.; Nogle, L.M.; McPhail, K.; Goeger, D.E.; Roberts, M.A.;  
Gerwick, W.H. Structure and biosynthesis of the jamaicamides, new mixed polyketide-peptide 
neurotoxins from the marine cyanobacterium Lyngbya majuscula. Chem. Biol. 2004, 11, 817–833. 
62. White, J.D.; Xu, Q.; Lee, C.S.; Valeriote, F.A. Total synthesis and biological evaluation of  
(+)-kalkitoxin, a cytotoxic metabolite of the cyanobacterium Lyngbya majuscula. Org. Biomol. 
Chem. 2004, 2, 2092–2102. 
63. Tripathi, A.; Puddick, J.; Prinsep, M.R.; Rottmann, M.; Chan, K.P.; Chen, D.Y.; Tan, L.T. 
Lagunamide C, a cytotoxic cyclodepsipeptide from the marine cyanobacterium Lyngbya 
majuscula. Phytochemistry 2011, 72, 2369–2375. 
64. Taori, K.; Paul, V.J.; Luesch, H. Structure and activity of largazole, a potent antiproliferative 
agent from the Floridian marine cyanobacterium Symploca sp. J. Am. Chem. Soc. 2008, 130, 
1806–1807. 
Mar. Drugs 2012, 10 2203 
 
 
65. Zeng, X.; Yin, B.; Hu, Z.; Liao, C.; Liu, J.; Li, S.; Li, Z.; Nicklaus, M.C.; Zhou, G.; Jiang, S. 
Total synthesis and biological evaluation of largazole and derivatives with promising selectivity 
for cancers cells. Org. Lett. 2010, 12, 1368–1371. 
66. Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J.; Mooberry, S.L. Isolation, structure 
determination, and biological activity of Lyngbyabellin A from the marine cyanobacterium 
Lyngbya majuscula. J. Nat. Prod. 2000, 63, 611–615. 
67. Luesch, H.; Yoshida, W.Y.; Harrigan, G.G.; Doom, J.P.; Moore, R.E.; Paul, V.J. Lyngbyaloside 
B, a new glycoside macrolide from a Palauan marine cyanobacterium, Lyngbya sp. J. Nat. Prod. 
2002, 65, 1945–1948. 
68. Pettit, G.R.; Hogan, F.; Xu, J.P.; Tan, R.; Nogawa, T.; Cichacz, Z.; Pettit, R.K.; Du, J.; Ye, Q.H.; 
Cragg, G.M.; et al. Antineoplastic agents. 536. New sources of naturally occurring cancer cell 
growth inhibitors from marine organisms, terrestrial plants, and microorganisms (1a,). J. Nat. 
Prod. 2008, 71, 438–444. 
69. Horgen, F.D.; Kazmierski, E.B.; Westenburg, H.E.; Yoshida, W.Y.; Scheuer, P.J. Malevamide D: 
Isolation and structure determination of an isodolastatin H analogue from the marine 
cyanobacterium Symploca hydnoides. J. Nat. Prod. 2002, 65, 487–491. 
70. Gross, H.; McPhail, K.L.; Goeger, D.E.; Valeriote, F.A.; Gerwick, W.H. Two cytotoxic 
stereoisomers of malyngamide C, 8-epi-malyngamide C and 8-O-acetyl-8-epi-malyngamide C, 
from the marine cyanobacterium Lyngbya majuscula. Phytochemistry 2010, 71, 1729–1735. 
71. Gutierrez, M.; Tidgewell, K.; Capson, T.L.; Engene, N.; Almanza, A.; Schemies, J.; Jung, M.; 
Gerwick, W.H. Malyngolide dimer, a bioactive symmetric cyclodepside from the panamanian 
marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2010, 73, 709–711. 
72. Golakoti, T.; Yoshida, W.Y.; Chaganty, S.; Moore, R.E. Isolation and structure determination of 
nostocyclopeptides A1 and A2 from the terrestrial cyanobacterium Nostoc sp. ATCC53789.  
J. Nat. Prod. 2001, 64, 54–59. 
73. Williams, P.G.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. Isolation and structure determination of 
obyanamide, a novel cytotoxic cyclic depsipeptide from the marine cyanobacterium Lyngbya 
confervoides. J. Nat. Prod. 2002, 65, 29–31. 
74. Zou, B.; Long, K.; Ma, D.W. Total synthesis and cytotoxicity studies of a cyclic depsipeptide 
with proposed structure of palau’amide. Org. Lett. 2005, 7, 4237–4240. 
75. Williams, P.G.; Yoshida, W.Y.; Quon, M.K.; Moore, R.E.; Paul, V.J. The structure of 
Palau’amide, a potent cytotoxin from a species of the marine cyanobacterium Lyngbya. J. Nat. 
Prod. 2003, 66, 1545–1549. 
76. Taniguchi, M.; Nunnery, J.K.; Engene, N.; Esquenazi, E.; Byrum, T.; Dorrestein, P.C.;  
Gerwick, W.H. Palmyramide A, a cyclic depsipeptide from a Palmyra Atoll collection of the 
marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2010, 73, 393–398. 
77. Luesch, H.; Pangilinan, R.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. Pitipeptolides A and B, new 
cyclodepsipeptides from the marine cyanobacterium Lyngbya majuscula. J. Nat. Prod. 2001, 64, 
304–307. 
78. Montaser, R.; Abboud, K.A.; Paul, V.J.; Luesch, H. Pitiprolamide, a proline-rich dolastatin 16 
analogue from the marine cyanobacterium Lyngbya majuscula from Guam. J. Nat. Prod. 2011, 
74, 109–112. 
Mar. Drugs 2012, 10 2204 
 
 
79. Wrasidlo, W.; Mielgo, A.; Torres, V.A.; Barbero, S.; Stoletov, K.; Suyama, T.L.; Klemke, R.L.; 
Gerwick, W.H.; Carson, D.A.; Stupack, D.G. The marine lipopeptide somocystinamide A 
triggers apoptosis via caspase 8. Proc. Natl. Acad. Sci. USA 2008, 105, 2313–2318. 
80. Harrigan, G.G.; Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Nagle, D.G.; Paul, V.J.; Mooberry, 
S.L.; Corbett, T.H.; Valeriote, F.A. Symplostatin 1: A dolastatin 10 analogue from the marine 
cyanobacterium Symploca hydnoides. J. Nat. Prod. 1998, 61, 1075–1077. 
81. Williams, P.G.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. Tasiamide, a cytotoxic peptide from the 
marine cyanobacterium Symploca sp. J. Nat. Prod. 2002, 65, 1336–1339. 
82. Williams, P.G.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. The isolation and structure elucidation 
of Tasiamide B, a 4-amino-3-hydroxy-5-phenylpentanoic acid containing peptide from the 
marine Cyanobacterium Symploca sp. J. Nat. Prod. 2003, 66, 1006–1009. 
83. Williams, P.G.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J. Tasipeptins A and B: New cytotoxic 
depsipeptides from the marine cyanobacterium Symploca sp. J. Nat. Prod. 2003, 66, 620–624. 
84. Williams, P.G.; Yoshida, W.Y.; Quon, M.K.; Moore, R.E.; Paul, V.J. Ulongapeptin, a cytotoxic 
cyclic depsipeptide from a Palauan marine cyanobacterium Lyngbya sp. J. Nat. Prod. 2003, 66, 
651–654. 
85. Mevers, E.; Liu, W.T.; Engene, N.; Mohimani, H.; Byrum, T.; Pevzner, P.A.; Dorrestein, P.C.; 
Spadafora, C.; Gerwick, W.H. Cytotoxic veraguamides, alkynyl bromide-containing cyclic 
depsipeptides from the marine cyanobacterium cf. Oscillatoria margaritifera. J. Nat. Prod. 2011, 
74, 928–936. 
86. Li, W.I.; Berman, F.W.; Okino, T.; Yokokawa, F.; Shioiri, T.; Gerwick, W.H.; Murray, T.F. 
Antillatoxin is a marine cyanobacterial toxin that potently activates voltage-gated sodium 
channels. Proc. Natl. Acad. Sci. USA 2001, 98, 7599–7604. 
87. Cao, Z.; Gerwick, W.H.; Murray, T.F. Antillatoxin is a sodium channel activator that displays 
unique efficacy in heterologously expressed rNav1.2, rNav1.4 and rNav1.5 alpha subunits. BMC 
Neurosci. 2010, 11, 154. 
88. Ma, D.; Zou, B.; Cai, G.; Hu, X.; Liu, J.O. Total synthesis of the cyclodepsipeptide apratoxin A 
and its analogues and assessment of their biological activities. Chemistry 2006, 12, 7615–7626. 
89. Liu, Y.; Law, B.K.; Luesch, H. Apratoxin a reversibly inhibits the secretory pathway by 
preventing cotranslational translocation. Mol. Pharmacol. 2009, 76, 91–104. 
90. Sumiya, E.; Shimogawa, H.; Sasaki, H.; Tsutsumi, M.; Yoshita, K.; Ojika, M.; Suenaga, K.; 
Uesugi, M. Cell-Morphology profiling of a natural product library identifies bisebromoamide 
and miuraenamide A as actin filament stabilizers. ACS Chem. Biol. 2011, 6, 425–431. 
91. Rubio, B.K.; Parrish, S.M.; Yoshida, W.; Schupp, P.J.; Schils, T.; Williams, P.G. Depsipeptides 
from a Guamanian Marine Cyanobacterium, Lyngbya bouillonii, with selective inhibition of 
serine proteases. Tetrahedron Lett. 2010, 51, 6718–6721. 
92. Gerwick, W.H.; Proteau, P.J.; Nagle, D.G.; Hamel, E.; Blokhin, A.V.; Slate, D.L. Structure of 
Curacin A, a novel antimitotic, antiproliferative, and brine shrimp toxic natural product from the 
Marine Cyanobacterium Lyngbya majuscula. J. Org. Chem. 1994, 59, 1243–1245. 
93. Mitra, A.; Sept, D. Localization of the antimitotic peptide and depsipeptide binding site on  
beta-tubulin. Biochemistry 2004, 43, 13955–13962. 
Mar. Drugs 2012, 10 2205 
 
 
94. Harrigan, G.G.; Yoshida, W.Y.; Moore, R.E.; Nagle, D.G.; Park, P.U.; Biggs, J.; Paul, V.J.; 
Mooberry, S.L.; Corbett, T.H.; Valeriote, F.A. Isolation, structure determination, and biological 
activity of dolastatin 12 and lyngbyastatin 1 from Lyngbya majuscula/Schizothrix calcicola 
cyanobacterial assemblages. J. Nat. Prod. 1998, 61, 1221–1225. 
95. Kwan, J.C.; Eksioglu, E.A.; Liu, C.; Paul, V.J.; Luesch, H. Grassystatins A–C from marine 
cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J. Med. Chem. 
2009, 52, 5732–5747. 
96. De Oliveira, E.O.; Graf, K.M.; Patel, M.K.; Baheti, A.; Kong, H.S.; MacArthur, L.H.; 
Dakshanamurthy, S.; Wang, K.; Brown, M.L.; Paige, M. Synthesis and evaluation of 
hermitamides A and B as human voltage-gated sodium channel blockers. Bioorg. Med. Chem. 
2011, 19, 4322–4329. 
97. Pereira, A.; Cao, Z.; Murray, T.F.; Gerwick, W.H. Hoiamide a, a sodium channel activator of 
unusual architecture from a consortium of two papua new Guinea cyanobacteria. Chem. Biol. 
2009, 16, 893–906. 
98. LePage, K.T.; Goeger, D.; Yokokawa, F.; Asano, T.; Shioiri, T.; Gerwick, W.H.; Murray, T.F. 
The neurotoxic lipopeptide kalkitoxin interacts with voltage-sensitive sodium channels in 
cerebellar granule neurons. Toxicol. Lett. 2005, 158, 133–139. 
99. Taori, K.; Paul, V.J.; Luesch, H. Kempopeptins A and B, serine protease inhibitors with different 
selectivity profiles from a marine cyanobacterium, Lyngbya sp. J. Nat. Prod. 2008, 71, 1625–1629. 
100. Matthew, S.; Paul, V.J.; Luesch, H. Largamides A–C, tiglic acid-containing cyclodepsipeptides 
with elastase-inhibitory activity from the marine cyanobacterium Lyngbya confervoides. Planta 
Med. 2009, 75, 528–533. 
101. Plaza, A.; Bewley, C.A. Largamides A–H, unusual cyclic peptides from the marine 
cyanobacterium Oscillatoria sp. J. Org. Chem. 2006, 71, 6898–6907. 
102. Matthew, S.; Ross, C.; Rocca, J.R.; Paul, V.J.; Luesch, H. Lyngbyastatin 4, a dolastatin 13 
analogue with elastase and chymotrypsin inhibitory activity from the marine cyanobacterium 
Lyngbya confervoides. J. Nat. Prod. 2007, 70, 124–127. 
103. Taori, K.; Matthew, S.; Rocca, J.R.; Paul, V.J.; Luesch, H. Lyngbyastatins 5–7, potent elastase 
inhibitors from Floridian marine cyanobacteria, Lyngbya spp. J. Nat. Prod. 2007, 70, 1593–1600. 
104. Kwan, J.C.; Taori, K.; Paul, V.J.; Luesch, H. Lyngbyastatins 8–10, elastase inhibitors with cyclic 
depsipeptide scaffolds isolated from the marine cyanobacterium Lyngbya semiplena. Mar. Drugs 
2009, 7, 528–538. 
105. Adams, B.; Porzgen, P.; Pittman, E.; Yoshida, W.Y.; Westenburg, H.E.; Horgen, F.D. Isolation 
and structure determination of malevamide E, a dolastatin 14 analogue, from the marine 
cyanobacterium Symploca laete-viridis. J. Nat. Prod. 2008, 71, 750–754. 
106. Gunasekera, S.P.; Miller, M.W.; Kwan, J.C.; Luesch, H.; Paul, V.J. Molassamide, a depsipeptide 
serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J. Nat. Prod. 
2010, 73, 459–462. 
107. Pereira, A.R.; Cao, Z.; Engene, N.; Soria-Mercado, I.E.; Murray, T.F.; Gerwick, W.H. 
Palmyrolide A, an unusually stabilized neuroactive macrolide from Palmyra Atoll cyanobacteria. 
Org. Lett. 2010, 12, 4490–4493. 
Mar. Drugs 2012, 10 2206 
 
 
108. Matthew, S.; Ross, C.; Paul, V.J.; Luesch, H. Pompanopeptins A and B, new cyclic peptides 
from the marine cyanobacterium Lyngbya confervoides. Tetrahedron 2008, 64, 4081–4089. 
109. Luesch, H.; Moore, R.E.; Paul, V.J.; Mooberry, S.L.; Corbett, T.H. Isolation of dolastatin 10 
from the marine cyanobacterium Symploca species VP642 and total stereochemistry and 
biological evaluation of its analogue symplostatin 1. J. Nat. Prod. 2001, 64, 907–910. 
110. Luesch, H.; Yoshida, W.Y.; Moore, R.E.; Paul, V.J.; Mooberry, S.L.; Corbett, T.H.  
Symplostatin 3, a new dolastatin 10 analogue from the marine cyanobacterium Symploca sp. 
VP452. J. Nat. Prod. 2002, 65, 16–20. 
111. Matthew, S.; Paul, V.J.; Luesch, H. Tiglicamides A–C, cyclodepsipeptides from the marine 
cyanobacterium Lyngbya confervoides. Phytochemistry 2009, 70, 2058–2063. 
112. Tan, L.T. Filamentous tropical marine cyanobacteria: a rich source of natural products for 
anticancer drug discovery. J. Appl. Phycol. 2010, 22, 659–676. 
113. Drew, L.; Fine, R.L.; Do, T.N.; Douglas, G.P.; Petrylak, D.P. The novel antimicrotubule agent 
cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer 
cells. Clin. Cancer Res. 2002, 8, 3922–3932. 
114. Sato, M.; Sagawa, M.; Nakazato, T.; Ikeda, Y.; Kizaki, M. A natural peptide, dolastatin 15, 
induces G2/M cell cycle arrest and apoptosis of human multiple myeloma cells. Int. J. Oncol. 
2007, 30, 1453–1459. 
115. Nagarajan, M.; Maruthanayagam, V.; Sundararaman, M. A review of pharmacological and 
toxicological potentials of marine cyanobacterial metabolites. J. Appl. Toxicol. 2012, 32, 153–155. 
116. Han, B.N.; McPhail, K.L.; Gross, H.; Goeger, D.E.; Mooberry, S.L.; Gerwick, W.H. Isolation 
and structure of five lyngbyabellin derivatives from a Papua New Guinea collection of the 
marine cyanobacterium Lyngbya majuscula. Tetrahedron 2005, 61, 11723–11729. 
117. Paradies, G.; Petrosillo, G.; Paradies, V.; Ruggiero, F.M. Mitochondrial dysfunction in brain 
aging: role of oxidative stress and cardiolipin. Neurochem. Int. 2011, 58, 447–457. 
118. Mammucari, C.; Rizzuto, R. Signaling pathways in mitochondrial dysfunction and aging. Mech. 
Ageing Dev. 2010, 131, 536–543. 
119. Sato, S.; Murata, A.; Orihara, T.; Shirakawa, T.; Suenaga, K.; Kigoshi, H.; Uesugi, M. Marine 
natural product aurilide activates the OPA1-mediated apoptosis by binding to prohibitin. Chem. 
Biol. 2011, 18, 131–139. 
120. Valko, M.; Leibfritz, D.; Moncol, J.; Cronin, M.T.; Mazur, M.; Telser, J. Free radicals and 
antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 
2007, 39, 44–84. 
121. Blokhina, O.; Virolainen, E.; Fagerstedt, K.V. Antioxidants, oxidative damage and oxygen 
deprivation stress: A review. Ann. Bot. 2003, 91, 179–194. 
122. Kelman, D.; Ben-Amotz, A.; Berman-Frank, I. Carotenoids provide the major antioxidant 
defence in the globally significant N2-fixing marine cyanobacterium Trichodesmium. Environ. 
Microbiol. 2009, 11, 1897–1908. 
123. Patel, A.; Mishra, S.; Ghosh, P.K. Antioxidant potential of C-phycocyanin isolated from 
cyanobacterial species Lyngbya, Phormidium and Spirulina spp. Indian J. Biochem. Biophys. 
2006, 43, 25–31. 
Mar. Drugs 2012, 10 2207 
 
 
124. Donepudi, M.; Grutter, M.G. Structure and zymogen activation of caspases. Biophys. Chem. 
2002, 101, 145–153. 
125. Fuentes-Prior, P.; Salvesen, G.S. The protein structures that shape caspase activity, specificity, 
activation and inhibition. Biochem. J. 2004, 384, 201–232. 
126. Wilkinson, J.C.; Cepero, E.; Boise, L.H.; Duckett, C.S. Upstream regulatory role for XIAP in 
receptor-mediated apoptosis. Mol. Cell. Biol. 2004, 24, 7003–7014. 
127. Okuno, S.; Shimizu, S.; Ito, T.; Nomura, M.; Hamada, E.; Tsujimoto, Y.; Matsuda, H. Bcl-2 
prevents caspase-independent cell death. J. Biol. Chem. 1998, 273, 34272–34277. 
128. Schrader, K.; Huai, J.; Jockel, L.; Oberle, C.; Borner, C. Non-Caspase proteases: Triggers or 
amplifiers of apoptosis? Cell. Mol. Life Sci. 2010, 67, 1607–1618. 
129. Turk, B. Targeting proteases: Successes, failures and future prospects. Nat. Rev. Drug Discov. 
2006, 5, 785–799. 
130. Williams, M.S.; Henkart, P.A. Apoptotic cell death induced by intracellular proteolysis.  
J. Immunol. 1994, 153, 4247–4255. 
131. Sagulenko, V.; Muth, D.; Sagulenko, E.; Paffhausen, T.; Schwab, M.; Westermann, F. Cathepsin 
D protects human neuroblastoma cells from doxorubicin-induced cell death. Carcinogenesis 
2008, 29, 1869–1877. 
132. Bidere, N.; Lorenzo, H.K.; Carmona, S.; Laforge, M.; Harper, F.; Dumont, C.; Senik, A. 
Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) 
relocation in T lymphocytes entering the early commitment phase to apoptosis. J. Biol. Chem. 
2003, 278, 31401–31411. 
133. Zaidi, N.; Kalbacher, H. Cathepsin E: A mini review. Biochem. Biophys. Res. Commun. 2008, 
367, 517–522. 
134. Ali, M.A.; Rosati, R.; Pettit, G.R.; Kalemkerian, G.P. Dolastatin 15 induces apoptosis and BCL-2 
phosphorylation in small cell lung cancer cell lines. Anticancer Res. 1998, 18, 1021–1026. 
135. Pedersen, S.F.; Hoffmann, E.K.; Mills, J.W. The cytoskeleton and cell volume regulation. Comp. 
Biochem. Physiol. A Mol. Integr. Physiol. 2001, 130, 385–399. 
136. Maeno, E.; Ishizaki, Y.; Kanaseki, T.; Hazama, A.; Okada, Y. Normotonic cell shrinkage 
because of disordered volume regulation is an early prerequisite to apoptosis. Proc. Natl. Acad. 
Sci. USA 2000, 97, 9487–9492. 
137. Fernandez-Segura, E.; Canizares, F.J.; Cubero, M.A.; Warley, A.; Campos, A. Changes in 
elemental content during apoptotic cell death studied by electron probe X-ray microanalysis. Exp. 
Cell Res. 1999, 253, 454–462. 
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
